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Abstract: Foods and food products that contain polyphenols are proposed to modulate risk
of cardiovascular disease. The aim of this three-arm, crossover, randomized, double-blind,
placebo-controlled intervention study was to examine the impact of Aronia melanocarpa juice (AMJ),
high-polyphenol (AMJ treatment, 1.17 g/100 mL polyphenols) and low-polyphenol (dAMJ treatment,
0.29 g/100 mL polyphenols) dose, on the transcriptome in peripheral blood mononuclear cells (PBMC)
of 19 subjects at cardiovascular risk. Transcriptome data were obtained by microarray. Bioinformatic
functional annotation analysis was performed on both the whole transcriptome datasets and the
differentially expressed genes (DEGs). Expression of selected DEGs was validated by RT-qPCR.
Administration of AMJ and dAMJ treatments during the two consecutive four-week treatment
periods had additive effects on PBMC transcriptome profiles, with the most pronounced and specific
effect noticed for AMJ in the last treatment period (TP3) of the trial. Between the high-dose and
low-dose treatments in TP3, there was a multitude of overlapping DEGs and DEG-enriched biological
processes and pathways, which primarily included immunomodulation and regulation of cell
proliferation/death. Increased expression of TNF, IL1B, IL8, RGS1, OSM, and DUSP2 in TP3 was
confirmed by RT-qPCR. The results suggest the immunomodulatory effects of prolonged habitual
consumption of polyphenol-rich aronia juice in individuals at cardiovascular risk.
Keywords: Aronia melanocarpa; polyphenol; peripheral blood mononuclear cells; messenger RNA
(mRNA); transcriptome; cardiovascular risk
1. Introduction
The majority of premature cardiovascular diseases (CVDs) can be prevented by changes in
lifestyle and diet, which is of particular importance, as CVDs represent a leading cause of death
worldwide [1]. Polyphenol-containing plant foods and derived products are suggested to modulate
CVD risk factors [2–4], but the evidence is still restricted and inconsistent. The findings also indicate
that higher intake of polyphenols might be more beneficial in individuals “at cardiovascular risk”
than in the healthy [5]. However, the recommended doses of specific polyphenol consumption, which
would result in the maximum benefit for humans, are not yet determined [6]. Only a few trials were
performed to examine the impact of well-defined doses of polyphenol-rich products on human health,
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compared to proper placebo without polyphenols. Generally, intervention studies are necessary to
validate the biological effects of plant foods and derived products that contain polyphenols in particular
subpopulations [7–9].
The biological effects of polyphenol application on lipopolysaccharide (LPS)-induced inflammation
in peripheral blood mononuclear cells (PBMC) were beneficial [10,11]. Other in vitro studies showed
that treatments with polyphenols were able to increase the constitutive and/or stimulated expression
of proinflammatory genes in PBMC and epidermal cells [12–16]. Aronia melanocarpa has a higher total
polyphenol content relative to other polyphenol-rich fruits [17,18]. Therefore, the present three-arm,
crossover, randomized, double-blind, placebo-controlled intervention study was designed to compare
the biological effects of two doses of a commercial Aronia melanocarpa juice. We aimed to explore the
impact of a high- and a low-polyphenol dose of aronia juice (including nutritionally matched placebo
beverage without polyphenols, as a control treatment) and the additive effects of the two polyphenol
doses on the whole transcriptome in PBMC in individuals at risk of CVD.
2. Materials and Methods
2.1. Study Design and Intervention Treatments
The present research (Figure 1) is designed as a sub-study of the original three-arm, crossover,
randomized, double-blind, placebo-controlled clinical trial registered at ClinicalTrials.gov as
NCT02800967. The original study included non-smoking adults at moderate risk of CVD, defined
as the presence of at least one of the following: increased body mass index (BMI) (25–30 kg/m2),
central obesity (waist circumference ≥80 cm for women and ≥94 cm for men), and high normal blood
pressure (systolic/diastolic blood pressure >120/80, ≤139/89 mm Hg). Exclusion criteria were as follows:
presence of chronic or acute disease, self-reported allergy to polyphenol-rich food, pregnancy, lactation,
blood donation 16 weeks before the start of the study, and parallel participation in another clinical trial.
The participants were asked to follow their habitual diet and usual physical activity, but to strictly
refrain from berries and berry products, during the course of the study. They were also requested to
avoid excess amounts of polyphenol-rich food, inclusive of green tea, olive oil, and excessive quantities
of nuts. They consumed study treatments as part of their habitual diet.
The original Aronia melanocarpa juice used in the study was registered at the Serbian Ministry of
Health as a dietary supplement and was donated from “Nutrika” LTD (Belgrade, Serbia). During the
three treatment periods of the NCT02800967 study, recruited participants were randomly assigned
to the following three 100 mL/day interventions: (1) original Aronia melanocarpa juice (assigned as
AMJ treatment), containing total polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L,
which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment (high dose); (2)
placebo beverage (assigned as PLB treatment), a formulation that has the same appearance, taste, and
nutritional composition of the original aronia juice, but without bioactive polyphenols [19]; (3) aronia
juice-based beverage (assigned as dAMJ treatment), produced by diluting the AMJ with the placebo
beverage (ratio 1:3) to contain a total polyphenol amount of 2942.77 mg GAE/L, which corresponds
to 0.29 g of total polyphenols per 100 mL of the allocated treatment (low dose). It was previously
reported that the daily amount of 100 mL of the placebo beverage is safe for human consumption [19].
Total polyphenols in the original aronia juice were determined using a modified Folin–Ciocalteu
method [20]. The study compliance was assessed according to returned empty bottles of intervention
drinks and self-reports.
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Figure 1. Study workflow. AMJ—treatment with original Aronia melanocarpa juice containing a total 
polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L, which corresponds to 1.17 g of 
total polyphenols per 100 mL of the allocated treatment (high dose); PLB—treatment with placebo 
beverage, a formulation that has the same appearance, taste, and nutritional composition of the 
original aronia juice, but without bioactive polyphenols; dAMJ—treatment with aronia juice-based 
beverage, made by diluting the AMJ with the PLB (ratio 1:3) and containing a total polyphenol 
amount of 2942.77 mg GAE/L, which corresponds to 0.29 g of total polyphenols per 100 mL of the 
allocated treatment (low dose). 
The original Aronia melanocarpa juice used in the study was registered at the Serbian Ministry of 
Health as a dietary supplement and was donated from “Nutrika” LTD (Belgrade, Serbia). During the 
three treatment periods of the NCT02800967 study, recruited participants were randomly assigned 
to the following three 100 mL/day interventions: (1) original Aronia melanocarpa juice (assigned as 
AMJ treatment), containing total polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L, 
which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment (high dose); 
(2) placebo beverage (assigned as PLB treatment), a formulation that has the same appearance, taste, 
and nutritional composition of the original aronia juice, but without bioactive polyphenols [19]; (3) 
aronia juice-based beverage (assigned as dAMJ treatment), produced by diluting the AMJ with the 
placebo beverage (ratio 1:3) to contain a total polyphenol amount of 2942.77 mg GAE/L, which 
corresponds to 0.29 g of total polyphenols per 100 mL of the allocated treatment (low dose). It was 
previously reported that the daily amount of 100 mL of the placebo beverage is safe for human 
consumption [19]. Total polyphenols in the original aronia juice were determined using a modified 
Folin–Ciocalteu method [20]. The study compliance was assessed according to returned empty 
bottles of intervention drinks and self-reports. 
The study protocol adhered to the regulations of the 1975 Declaration of Helsinki, and was 
approved by Clinical Hospital Centre Zemun, Belgrade, Serbia, Ethics Committee Approval, No: 
2125, 2013. Written informed consent was given by all participants before the commencement of the 
study.  
2.2. Sample Collection 
i r 1. t r fl . J treat e t it origi al ronia ela oc r j i c t i i t t l
olyphenol amount of 1 ,771.09 mg allic acid equivalent (GAE)/L, which corresponds to 1.17 g of total
p lyphenols per 100 mL of the allocated tre tment (high dose); PLB—treatment with placebo beverage,
a formulation that has the same appearance, taste, and nutritional compositi of the original aronia
juice, but without bioactive polyphenols; dAMJ—treatment with aronia juice-based beverage, made
by diluting the AMJ with the PLB (ratio 1:3) and containing a total polyphenol amount of 2942.77 mg
GAE/L, which corresponds to 0.29 g of total polyphenols per 100 mL of the allocated treat ent (low
dose).
The study protocol adhered to the regulations of the 1975 Declaration of Helsinki, and was
approved by Clinical Hospital Centre Zemun, Belgrade, Serbia, Ethics Committee Approval, No: 2125,
2013. Written informed consent was given by all participants before the commencement of the study.
2.2. Sample Collection
Study participants were instructed for overnight fasting and venous blood was collected the next
morning between 8:00 and 9:00 a.m., into the sample tubes for serum and ethylenediaminetetraacetic
aci evacuated tubes. The sample collection was done at t o time points—before a d after the
corresponding four-week treatments (AMJ, dAMJ, and PLB).
2.3. Assessment of Study Variables
For determination of baseline dietary intake, trained staff conducted structured interviews with
study subjects and collected data by using a food frequency questionnai e a d repeated 24-hour
dietary re ls. The subjects were assisted with a 125-item photo-booklet comprising simple foods
and composite dishes [21]. Data from di tary recalls were analyzed by use of the nutritional platform
for comprehensive diet evaluation [21,22]. Of relevance for this study, no outliers were identified
with regard to hab tual dietary intakes of total energy nd main nutrients, among the study subjects
upon enrollmen .
Bio-impedance analyzer TANITA UM072 balance (TANITA Health Equipment H.K. Ltd) was used
for determination of body weight. Total cholesterol, as well as high-density (HDL-C) and low-density
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(LDL-C) lipoprotein cholesterols, triacylglycerols, and glucose from serum were assessed by Roche
Diagnostics Kits, using the Cobas c111 analyzer (Roche Diagnostics, Basel, Switzerland).
2.4. Isolation of PBMC and Preparation of the Total RNA
The peripheral blood samples of each subject were assembled at two time points—before and
after treatment, for the corresponding treatment period(s). The PBMC were isolated with lymphocyte
separation medium (PAA, GE Healthcare), and the total RNA was extracted from PBMC by using
TRI Reagent (Ambion, Life Technologies). The quantity of total RNA was estimated by BioSpecnano
spectrophotometer (Shimadzu Biotech). Bioanalyzer 2100 was employed for the assessment of total
RNA quality/integrity, by deployment of the RNA 6000 Nano Kit (Agilent, Santa Clara, CA, USA). All
RNA samples had an RNA integrity number (RIN) >7 and were kept at −80 ◦C prior to use.
2.5. Samples for Microarray Analysis
The microarray analysis comprised 19 subjects (12 men and seven women). There were 32
analyzed treatments in three successive treatment periods, for which the microarray was carried out at
two time points (before and after each treatment): 15 AMJ treatments, 13 dAMJ treatments, and four
PLB treatments (Table S1, Supplementary Materials). We investigated the effects of AMJ and dAMJ
treatments on the PBMC messenger RNA (mRNA) expression profile during the second and third
treatment periods (TP2 and TP3), as well as after the PLB treatment during the first treatment period
(TP1) (Figure 1). The reasons for choosing this study design were three-fold: (1) the placebo treatment
prior to polyphenol-containing treatments provided us with a polyphenol-lacking placebo arm, to
determine the exclusive effects of polyphenol-containing treatments; (2) the inclusion of two treatments
with different polyphenol content enabled a discussion on high vs. low polyphenol dose, conferring
the role of the public health relevance of the intervention effects; (3) the subsequent allocation to either
low- or high-polyphenol content treatment provided us with information on the additive (cumulative)
effects of polyphenol consumption. Overall, during TP1, four subjects were allocated to PLB. During
TP2, there were nine subjects allocated to AMJ and eight subjects allocated to dAMJ, and, further on,
six subjects allocated to AMJ and five subjects allocated to dAMJ during TP3 (Table S1, Supplementary
Materials). To examine the effects of two successive treatments on the PBMC mRNA expression profile,
with respect to their order in TP2 and TP3, AMJ→ dAMJ or dAMJ→ AMJ (after the PLB treatment
during TP1), respectively, there were five subjects with an AMJ→ dAMJ and six subjects with a dAMJ
→ AMJ successive treatment transition (Table S1, Supplementary Materials).
2.6. Microarray PBMC mRNA Expression Profiling and Determination of Differentially Expressed Genes
The total RNA (200 ng) from PBMC was used for amplification of the poly(A) RNA,
by in vitro transcription of biotin-aRNA, using a TargetAmp™- Nano Labeling Kit for
Illumina®Expression BeadChip®(Epicentre, Madison, WI, USA). Biotin-aRNA purification was
done with RNeasy®MinElute®Cleanup kit (Qiagen, Hilden, Germany), and the purified biotin-aRNA
was quantified using a BioSpecnano spectrophotometer (Shimadzu Biotech, Kyoto, Japan). The
Whole-Genome Gene Expression Direct Hybridization Assay (HumanHT-12 v.4 Expression BeadChip
Kit, Illumina Inc., San Diego, CA, USA) was used for hybridization of biotin-aRNA (750 ng) to each array.
The beadchips were scanned with iScan System (Illumina Inc., San Diego, CA, USA). Initial quality
control of gene expression data was done using control metrics in GenomeStudio Gene Expression
Module v1.9 (Illumina Inc., San Diego, CA, USA), and subsequent quality assessment was done using
the Illumina QC pipeline of the ArrayAnalysis.org tool [23]. The results from GenomeStudio Gene
Expression Module v1.9 were exported and further analyzed by R/Bioconductor software [24] and
limma v3.32.0 package for linear modeling of microarray data [25,26]. The neqc function was used
for pre-processing steps (background correction, quantile normalization, log2 transformation, and
removing the control probes) [27]. Unexpressed and low-expression probes were filtered out (filtering
conditions: probes expressed in at least four samples, by a detection p-value < 0.01). The quality grade
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of probes was assigned using IlluminaHumanv4.db v1.26.0 package, and additional removal of “bad”
probes (probes that match repeat sequences, intergenic or intronic regions, or probes unlikely to provide
a specific signal for any transcript) and “no match” probes (probes not matching any genomic region
or transcript) was done. The duplicateCorrelation function was used in a random effect approach, to
handle blocking on the same subject [28], while the arrayWeights function was applied to down-weight
lesser-quality arrays, thus enhancing the accuracy and power of the differential expression analysis [29].
Differentially expressed genes (DEGs) were determined for the defined contrast matrix (comparisons
of points before and after the analyzed treatments) based on an analogic design matrix, by using the
linear model fit in conjunction with empirical Bayes statistics, which was based on a moderated t-test
of the limma package [25]. Differential expression of genes was defined at an adjusted p-value < 0.05
(Benjamini and Hochberg’s, BH, method of adjustment for multiple testing was used) and absolute
logarithmic fold change (|log2FC|) > 0.5. Expression data were stored within the Gene Expression
Omnibus (GEO) repository under accession No GSE145034, using GEO Data Submission Report
Plug-in v2.0.0 for GenomeStudio software (Illumina Inc., San Diego, CA, USA).
2.7. Bioinformatic Analysis
The computational method Gene Set Enrichment Analysis (GSEA) [30] was applied for detection
of statistically significant concordant expression differences in a priori defined sets of genes, between
two biological states (herein: before and after treatment). The GSEA includes the whole transcriptome
dataset, instead of arbitrarily determined DEGs, allowing the identification of even subtle gene
expression changes with biological significance. The subset of a gene set members, which contributes
most to the enrichment score (ES), is defined as the leading-edge subset, being also presented as the
core of a gene set that accounts for the enrichment signal. The current enrichment analysis of the
PBMC transcriptome was employed for an overview of the enriched biological processes. It involved
Hallmark gene sets (collection of gene sets obtained by assembling many database gene sets to show
well-defined biological processes) exported from the online Molecular Signatures Database (MsigDB)
v6.1, with the chip annotation file ilmn_HumanHT_12_V4_0_R1_15002873_B.chip used to collapse
each probe set of the expression dataset into a single vector for each gene.
For a more integrative information about treatment effects, the enrichment analysis was performed
on the sets of identified DEGs by applying an online functional annotation tool DAVID v6.8 (Database
for Annotation, Visualization and Integrated Discovery) [31], using Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) databases. The associated GO terms having an EASE
score (modified Fisher’s exact test p-value) < 0.1 were considered significantly enriched in DEGs and,
hence, were further interpreted in the GO enrichment analysis.
2.8. Validation of PBMC Gene Expression by Reverse Transcription Quantitative Polymerase Chain Reaction
(RT-qPCR)
Validation of identified transcriptomic differences (after vs. before each analyzed treatment period)
was performed by RT-qPCR, to measure expression of the selected genes. The criteria for selection of
genes to be validated were based on the defined cutoff parameters of differential gene expression, as
well as on bioinformatic analysis. Validation of expression was done for the following genes: IL1B,
TNF, IL8, RGS1, OSM, and DUSP2. The analysis included 45 treatments: 18 AMJ, 18 dAMJ, and nine
PLB, in 19 subjects. There were nine subjects with AMJ→ dAMJ and eight subjects with dAMJ→ AMJ
successive treatment transitions (Table S1, Supplementary Materials).
The total RNA (500 ng) extracted from each PBMC sample was treated with DNAseI (Thermo Fisher
Scientific Inc., Waltham, MA, USA), to avoid contamination with genomic DNA; subsequently, reverse
transcription was done by using a RevertAid First Strand complementary DNA (cDNA) Synthesis kit
(Thermo Fisher Scientific Inc., Waltham, MA, USA), with Oligo(dT)18 primer. Real-time qPCR reactions
were performed in duplicate on an Applied Biosystems Real-time 7500 system (Applied Biosystems,
Foster City, CA, USA), using TaqMan®gene expression assays (Applied Biosystems, Foster City, CA,
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USA) for the target genes: IL1B (Hs01555410_m1), TNF (Hs00174128_m1), IL8 (Hs00174103_m1), RGS1
(Hs01023772_m1), OSM (Hs00171165_m1), and DUSP2 (Hs00358879_m1), and a reference gene, PPIA
(Hs99999904_m1). As it is stably expressed, PPIA was used to normalize the expression of target genes.
The relative expression (mRNA) levels of each target gene were quantified as the mean normalized
expression, based on the comparative Ct method [32].
2.9. Statistical Analysis
The distribution of continuous variables, including age, BMI, serum glucose, triacylglycerols, total
cholesterol, LDL-C, HDL-C, and relative mRNA expression levels of the validated genes, was tested by
Shapiro–Wilk’s test. Within-group comparisons (after vs. before each treatment period) were done
using t-test for dependent samples or Wilcoxon matched pairs test, while between-group comparisons
were done by t-test or Mann–Whitney U test, for normal or skewed distribution, respectively. In the
statistical tests, p-values < 0.05 were considered statistically significant. The statistical analysis was
accomplished using Statistica 8.0 software package (StatSoft, Inc. 1984-2007).
3. Results
3.1. Determination of PBMC DEGs for the Applied Treatments
The DEGs identified by analyzing the PBMC transcriptome of study subjects, according to applied
treatments, are shown in Table 1 and Table S2 (Supplementary Materials). Two treatments, PLB TP1
(comparison after vs. before TP1) and dAMJ TP2 (after vs. before TP2), resulted in no DEGs. The
largest number of DEGs was determined for AMJ TP3 (after vs. before TP3). For single treatments, as
well as for successive treatment transitions, most DEGs were upregulated (Table S2, Supplementary
Materials).
Table 1. The number of differentially expressed genes in peripheral blood mononuclear cells of the
study subjects, identified in different treatment periods.
Comparison Number of DEGs *
PLB aTP1 vs. PLB bTP1 0
AMJ aTP2 vs. AMJ bTP2 78
dAMJ aTP2 vs. dAMJ bTP2 0
AMJ aTP3 vs. AMJ bTP3 172
dAMJ aTP3 vs. dAMJ bTP3 62
AMJ aTP3 vs. dAMJ bTP2 115
dAMJ aTP3 vs. AMJ bTP2 51
DEGs—differentially expressed genes; * differential gene expression was defined at an adjusted p-value < 0.05 (after
Benjamini and Hochberg’s correction) and absolute logarithmic fold change (|log2FC|) > 0.5; AMJ—treatment with
original Aronia melanocarpa juice containing a total polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L,
which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment (high dose); PLB—treatment
with placebo beverage, a formulation that has the same appearance, taste, and nutritional composition of the
original aronia juice, but without bioactive polyphenols; dAMJ—treatment with aronia juice-based beverage, made
by diluting the AMJ with the PLB (ratio 1:3) and containing a total polyphenol amount of 2942.77 mg GAE/L, which
corresponds to 0.29 g of total polyphenols per 100 mL of the allocated treatment (low dose); aTP—after treatment
period; bTP—before treatment period.
According to the heatmap of DEG overlap (Figure 2), the highest number of common DEGs
are shared between AMJ TP3 and dAMJ→ AMJ successive treatment transition (after TP3 AMJ vs.
before TP2 dAMJ). Moreover, there is a noticeable DEG overlap between dAMJ TP3 and AMJ→ dAMJ
successive treatment transition (after TP3 dAMJ vs. before TP2 AMJ). The overlap is negligible between
AMJ TP2 and every other treatment/successive treatment transition (Figure 2).
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Figure 2. Frequency of overlap of differentially expressed genes in the study subjects, between differe t
treatments/treat ent pe iods. AMJ—treatment with original Aronia mela ocarpa juice containing a total
polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L, which corresponds to 1.17 g of
total polyphenols per 100 mL of the allocated tr atment (high dose); dAMJ—treatment with aronia
juice-based beverage, made by diluting the AMJ with placebo beverage (ratio 1:3) and containing a total
polyphenol amount of 2942.77 mg GAE/L, which corresponds to 0.29 g of total polyphenols per 100 mL
of the allocated treatment (low dose); aTP—after treatment period; bTP—before treatment period.
3.2. GSEA Analysis of PBMC Transcriptome
The GSEA results for the whole PBMC transcriptome datasets are given in Table 2 and Figure 3.
The analysis disclosed 10 Hallmark gene sets significantly enriched and upregulated after TP3 AMJ,
in comparison to before TP3 AMJ (Table 2). Among them, the top three enriched gene sets are TNFA
signaling via NFKB, apoptosis, and inflammatory response. The enrichment plots of these three gene
sets are shown in Figure 3. TNFA signaling via NFKB was the only Hallmark gene set significantly
enriched, after vs. before TP3 dAMJ (Table 2). There were no Hallmark gene sets significantly enriched
in AMJ TP2 (Table 2).
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Table 2. Gene sets significantly enriched after the given treatment.
Comparison Enriched HALLMARK GENE SET Size ES NES FDR q-val
AMJ aTP3 vs. AMJ bTP3 HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 0.622 3.05 0.000
HALLMARK_APOPTOSIS 161 0.399 1.8 0.002
HALLMARK_INFLAMMATORY_RESPONSE 200 0.370 1.82 0.003
HALLMARK_INTERFERON_GAMMA_RESPONSE 199 0.370 1.80 0.002
HALLMARK_INTERFERON_ALPHA_RESPONSE 96 0.354 1.54 0.034
HALLMARK_P53_PATHWAY 196 0.306 1.49 0.047
HALLMARK_HYPOXIA 197 0.304 1.48 0.045
HALLMARK_UV_RESPONSE_UP 158 0.314 1.48 0.041
HALLMARK_IL6_JAK_STAT3_SIGNALING 87 0.342 1.47 0.039
HALLMARK_KRAS_SIGNALING_UP 200 0.298 1.46 0.037
dAMJ aTP3 vs. dAMJ bTP3 HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 0.492 2.35 0.000
AMJ aTP2 vs. AMJ bTP2 None
Enriched gene sets were calculated for the phenotype after treatment (bold), compared to phenotype before treatment,
in the study subjects; size—number of genes included in the gene set; ES—enrichment score, reflects the degree
to which a gene set is over-represented in a phenotype after treatment; NES—normalized enrichment score, the
enrichment score for the gene set after it is normalized across the analyzed gene sets; FDR q-val—false discovery rate,
the estimated probability that the normalized enrichment score represents a false positive finding; AMJ—treatment
with original Aronia melanocarpa juice containing a total polyphenol amount of 11,771.09 mg gallic acid equivalent
(GAE)/L, which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment (high dose);
dAMJ—treatment with aronia juice-based beverage, made by diluting the AMJ with placebo beverage (ratio 1:3)
and containing a total polyphenol amount of 2942.77 mg GAE/L, which corresponds to 0.29 g of total polyphenols
per 100 mL of the allocated treatment (low dose); aTP—after treatment period; bTP—before treatment period.
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Comparison Enriched HALLMARK GENE SET Size ES NES FDR q-val 
AMJ aTP3 vs. AMJ bTP3 HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 0.622 3.05 0.000 
 HALLMARK_APOPTOSIS 161 0.399 1.8 0.002 
 HALLMARK_INFLAMMATORY_RESPONSE 200 0.370 1.82 0.003 
 HALLMARK_INTERFERON_GAMMA_RESPONSE 199 0.370 1.80 0.002 
 HALLMARK_INTERFERON_ LPHA_R PONSE 96 0.354 1.54 0.034 
 HALLMARK_P53_PATHWAY 196 0.306 1.49 0.047 
 HALLMARK_HYPOXIA 197 0.304 1.48 0.045 
 HALLMARK_UV_RESPONSE_UP 158 0.314 .48 0.041 
 HALLMARK_IL6_JAK_STAT3_SIGNALING 87 0.342 47 0.039 
 HALLMARK_ RAS_SIGNALI G_UP 200 0.298 .46 0.037 
dAMJ aTP3 vs. dAMJ bTP3 HALLMARK_TNFA_SIGNALING_VIA_NFKB 199 0.492 2.35 0.000 
AMJ aTP2 vs. AMJ bTP2 None     
Enriched gene sets were calculated for the phenotype after treatment (bold), compared to phenotype 
before treatment, in the study subjects; size—number of genes included in the gene set; 
ES—enrichment score, reflects the degree to which a gene set is over-represented in a phenotype 
after treatment; NES—normalized enrichment score, the enrichment score for the gene set after it is 
normalized across the analyzed gene sets; FDR q-val—false discovery rate, the estimated probability 
that the normalized enrichment score represents a false positive finding; AMJ—treatment with 
original Ar nia melanocarpa juice containing a total polyphenol amount of 11,771.09 mg gallic acid 
equivalent (GAE)/L, which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated 
treatment (high dose); dAMJ—treatment with aronia juice-based beverage, made by diluting the 
J with placebo beverage (ratio 1:3) and cont ining a total polyphenol amount of 2942.77 mg 
GAE/L, which corresponds to 0.29 g of total polyphenols per 100 mL of the allocated treatment (low 
dose); aTP—after treatment period; bTP—before treatment period. 
 
Figure 3. Enrichment plots of top three enriched Hallmark gene sets for the phenotype AMJ aTP3, 
compared to phenotype AMJ bTP3. Each enrichment plot shows profile of the running enrichment 
score and positions of gene set constituents on the rank ordered list; AMJ—treatment with original 
Aronia melanocarpa juice containing a total polyphenol amount of 11,771.09 mg gallic acid equivalent 
(GAE)/L, which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment 
(high dose); aTP—after treatment period; bTP—before treatment period. 
Figure 3. Enrich t l t f t three enriched Hallmark gene sets for the phenotype AMJ aTP3,
compared to phenot e J 3. Each enrichment plot shows profile of the running enrichment
score and positions of gene set constituents on the rank ordered list; AMJ—treatment with original
Aronia melanocarpa juice containing a total polyphenol amount of 11,771.09 mg gallic acid equivalent
(GAE)/L, which corresponds to 1.17 g of total polyphenols per 100 mL of the allocated treatment (high
dose); aTP—after treatment period; bTP—before treatment period.
3.3. Enrichment Analysis of DEGs
The results of enrichment analysis of DEGs are presented in Table S3 (Supplementary Materials).
The analysis involved all DEGs and was performed in the categories of GO Biological Process (BP) (GO:
BP) and KEGG pathway terms. As expected, based on total number and overlapping of DEGs (Table 1,
Figure 2), the most numerous terms, as well as overlapping terms, significantly enriched in DEGs, were
found for AMJ TP3 and dAMJ→ AMJ successive treatment transition. Among the top-overlapping
significantly enriched biological terms were primarily those related to immunity and also those related
to regulation of cell proliferation and death, including the following processes: inflammatory response,
cellular response to tumor necrosis factor, negative regulation of cell proliferation, immune response,
apoptotic process, monocyte chemotaxis, neutrophil chemotaxis, cellular response to interleukin-1,
and lymphocyte chemotaxis. The top-overlapping enriched KEGG pathways, TNF signaling pathway,
Toll-like receptor signaling pathway, NF-kappa B signaling pathway, cytokine–cytokine receptor
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interaction, and chemokine signaling pathway, were in line with GSEA analysis performed on the
entire transcriptome, thus confirming the true origin of treatment effect from identified DEGs. The
latter biological processes and pathways were also depicted amid the top-overlapping in the following
comparisons: between AMJ TP3 and dAMJ TP3, between dAMJ TP3 and AMJ→ dAMJ successive
treatment transition, and between dAMJ→ AMJ and AMJ→ dAMJ transitions. For each of these three
comparisons, most of the significantly enriched biological terms overlapped. The PBMC response
specific for AMJ TP3 encompassed several DEG-enriched processes related to metabolism and reactive
oxygen species: response to glucocorticoid, sequestering of triglycerides, negative regulation of lipid
storage, cellular response to oxidative stress, and regulation of reactive oxygen species metabolic
process (Table S3, Supplementary Materials). Only a few general processes (protein phosphorylation,
protein autophosphorylation, transcription from RNA polymerase II promoter, and protein K63-linked
deubiquitination) overlapped between AMJ TP2 and other treatments/successive treatment transitions.
The non-overlapping significantly enriched biological terms found for all stated comparisons were
mostly related also to general molecular processes. With regard to the present enrichment analysis,
it could be concluded that there are no specific effects of dAMJ→ AMJ and AMJ→ dAMJ transitions
and, therefore, these two successive treatment transitions were excluded from validation of the
identified transcriptomic differences.
3.4. RT-qPCR Validation of Selected DEGs
Validation of identified PBMC transcriptomic differences, for applied treatments, comprised the
RT-qPCR relative expression quantification of the following DEGs: IL1B, TNF, IL8, DUSP2, OSM, and
RGS1 (Table 3). For all analyzed treatments except AMJ TP2, the selected DEGs had a significantly
increased expression, demonstrated through log2FC and adjusted p-value (Table S2, Supplementary
Materials), as well as an involvement in differentially affected biological processes and pathways of
interest, related to immunity or regulation of cell proliferation/death and overlapped between the
treatments (Table S3, Supplementary Materials). As shown in Table S4 (Supplementary Materials), the
vast majority of microarray results were replicated by qPCR, including the comparisons after vs. before:
TP2 AMJ, TP2 dAMJ, and TP3 AMJ. The comparison after vs. before TP3 dAMJ showed a significant
upregulation of three genes (TNF, IL8, and DUSP2) by qPCR, while microarray resulted in no significant
differences regarding the expression of above-mentioned genes. More interestingly, microarray revealed
no DEGs for the comparison after vs. before TP1 PLB (placebo), while four of six genes selected for
validation (IL8, DUSP2, OSM, and RGS1) were significantly upregulated by qPCR. Nevertheless, the
significant values of qPCR fold change of expression were evidently lower for placebo, compared to
other treatments (Table S4, Supplementary Materials). This means that, if placebo affected the gene
expression, these effects were considerably weaker in comparison to the effects of polyphenol-containing
aronia juice treatments. Yet, as both low-dose and high-dose polyphenol treatments contained all
placebo components, and significant expression changes of the above-mentioned genes were not
detected by microarray/qPCR for either of the two polyphenol-containing treatments in TP2, it is
unlikely that placebo components had an impact on gene expression. The significant gene expression
changes could be due to a lack of the run-in period preceding the TP1.
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Table 3. The candidate genes’ expression changes in peripheral blood mononuclear cells of the study
subjects, during different treatment periods, observed by RT-qPCR.
Gene AMJaTP2 vs.AMJbTP2
dAMJaTP2 vs.
dAMJbTP2
AMJaTP3 vs.
AMJbTP3
dAMJaTP3 vs.
dAMJbTP3
PLBaTP1 vs.
PLBbTP1
FC p * FC p * FC p * FC p * FC p *
IL1B 0.79 0.799 1.01 0.948 26.41 † 0.025 47.65 † 0.021 1.50 0.173
TNF 0.70 0.284 0.96 0.594 23.64 † 0.012 16.07 0.021 1.32 0.139
IL8 0.87 0.508 3.06 0.021 9.14 † 0.093 30.11 0.008 3.50 0.008
DUSP2 0.93 0.646 1.04 0.767 5.34 † 0.036 4.89 0.015 1.58 0.017
OSM 0.96 0.721 1.08 0.515 3.62 † 0.025 3.89 † 0.001 2.00 0.011
RGS1 1.16 0.878 1.1 0.953 4.04 † 0.036 4.83 † 0.001 1.25 0.028
FC—fold change; * t-test for dependent samples/Wilcoxon matched pairs test; † significantly different expression
level in microarray analysis for the same treatment; AMJ—treatment with original Aronia melanocarpa juice containing
a total polyphenol amount of 11,771.09 mg gallic acid equivalent (GAE)/L, which corresponds to 1.17 g of total
polyphenols per 100 mL of the allocated treatment (high dose); PLB—treatment with placebo beverage, a formulation
that has the same appearance, taste, and nutritional composition of the original aronia juice, but without bioactive
polyphenols; dAMJ—treatment with aronia juice-based beverage, produced by dilution of the AMJ with the
PLB (ratio 1:3) and containing a total polyphenol amount of 2942.77 mg GAE/L, which corresponds to 0.29 g of
total polyphenols per 100 mL of the allocated treatment (low dose); aTP—after treatment period; bTP—before
treatment period.
3.5. Effects of the Applied Treatments on Cardio-Metabolic Parameters and Leukocyte Count
In subjects involved in microarray analysis, comparisons of effects after vs. before each treatment
(AMJ, dAMJ, PLB) in each of three treatment periods, with regard to anthropometric and metabolic
parameters (BMI, serum glucose, triacylglycerols, total cholesterol, HDL-C, LDL-C) and leukocyte
count (total leukocytes, % mononuclear cells, % lymphocytes, % monocytes, % granulocytes), resulted
in no significant differences (p (t-test for dependent samples/Wilcoxon matched pairs test) > 0.05), with
exception of HDL-C after vs. before TP2 AMJ (1.4 ± 0.4 mmol/L vs. 1.5 ± 0.4 mmol/L; p (t-test for
dependent samples) = 0.002) (data not shown) and glucose after vs. before TP3 dAMJ (4.5 ± 0.3 mmol/L
vs. 4.9 ± 0.2 mmol/L, p (t-test for dependent samples) = 0.008) (Table S5, Supplementary Materials).
Both HDL-C and glucose levels were in the clinical ranges. The comparisons of treatment effects
toward cardio-metabolic parameters and leukocyte count are presented for TP3 (Tables S5 and S6,
Supplementary Materials), as the period characterized by the pronounced and specific effects of aronia
juice consumption on gene expression changes.
4. Discussion
In nutrigenomics, gene expression profiling is used to investigate transcriptional changes indicative
of mechanisms associated with nutrients and diet. In this study, we demonstrated that the consumption
of two different single doses of polyphenol-containing Aronia melanocarpa juice during the two
consecutive four-week treatment periods had additive effects on PBMC gene expression profiles in
subjects at risk of CVD. Comparison of after vs. before the second treatment period (TP2) resulted
in the DEG-enriched biological terms depicting an unspecific cellular response, mainly related to
general molecular processes, solely for the high-dose polyphenol aronia juice treatment (AMJ), while
consumption of low-dose polyphenol juice (dAMJ) resulted in no DEGs. The most pronounced and
specific effect of aronia juice consumption on gene expression changes was noticed in the group that
received high-dose polyphenol aronia juice in the last treatment period (TP3) of the six-month trial.
Likewise, although after acute intake, extra virgin olive oil rich in polyphenols had the strongest impact
on modulation of transcription of genes in healthy subjects, while weaker effects were revealed after
low-polyphenol extra virgin olive oil consumption [33].
A multitude of overlapping DEGs and biological processes and pathways were observed between
high-dose and low-dose treatments in the last treatment period, although the low-dose aronia juice
intake had a weaker impact on differential gene expression. The top-overlapping significantly enriched
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biological processes for high- and low-dose polyphenol aronia juice were related to immunomodulation:
immunity and immune response, regulation of cell proliferation, death and apoptosis, inflammatory
response, chemotaxis of immune cells, and cellular response to tumor necrosis factor. Pathway analysis,
after TP3 high-dose polyphenol intake, confirmed the enrichment in DEGs of the TNF signaling
pathway, Toll-like receptor signaling pathway, NF-kappa B signaling pathway, cytokine–cytokine
receptor interaction, and chemokine signaling pathway.
Distinct upregulation of IL1B and TNF was detected exclusively after two consecutive treatment
periods. This result indicates a molecular shift toward a proinflammatory environment after the
long-term consumption of polyphenol-rich beverage, which is not a favorable scenario with regard to
CVD. There is in vitro evidence that treatment of immune cells with resveratrol resulted in either up-
or downregulation of expression of TNF, IL1B, and IL8 in a cell- and context-dependent manner [34].
In line with our findings, the in vitro studies revealed that treatments with polyphenols were able
to increase the constitutive and/or stimulated expression of these genes [12–16]. In cultured human
PBMC, treatment with resveratrol and TLR agonists potentiated the production of TNF, along with
NF-κB pathway activation [12], while cocoa procyanidins caused an increase in TNF and IL1B
in both resting and phytohemagluttinin-stimulated cells [13,14]. The treatment of normal human
epidermal keratinocytes with resveratrol (alone or in combination with TNF) induced a delayed,
long-lasting over-expression of IL8 [16], a known proinflammatory marker. The majority of previous
studies presented in vitro data with respect to application of polyphenols, yet, the clinical studies
utilizing foods or beverages offered a more realistic assessment of the real-life effects. During the last
decade, there was a persistent need for studies like ours, which improve knowledge on the molecular
background of potential polyphenol effects. In a nine-week interventional trial on obese individuals,
IL1B levels were significantly higher in supernatants of LPS-activated PBMC from the individuals
who were fed grape compared to those fed placebo, for a three-week period [15]. The stated data
indicate that dietary plant products, which contain polyphenols, modulate the inflammatory process
in subjects with pre-stimulated inflammatory cells. The observation that resveratrol induced the
expression of TNF in TLR agonist-stimulated PBMC indicates that the increased TNF plasma levels
detected in healthy individuals 24 h after the treatment with resveratrol could be owing to local
immunopotentiation by TLR-stimulating factors from the gut microenvironment, suggesting that
consumption of polyphenol-containing products might stimulate leukocyte activity in the gut [12].
Herein, we did not detect any significant change in leukocyte count after TP3. The increased release of
IL1B and IL6 from the LPS-stimulated monocytes of the healthy obese individuals after three-week
consumption of grape powder was related to the stimulatory effects of these two cytokines on
macrophage- and neutrophil-mediated phagocytosis of pathogens [15]. The authors proposed that
grape consumption-associated sensitization of the monocytes of obese subjects to raise the production
of proinflammatory cytokines in response to a bacterial stimulus might be favorable, as the obese are
at an increased risk of infections [15]. Given the established multifactorial nature of a cellular and
systemic response to polyphenol treatments, it is crucial to discuss our results in terms of facilitation
of applicability of treatments achievable by dietary means. The high dose polyphenols consumed in
this study would hardly be achievable by dietary means, but it provides novel data on unexpected
proinflammatory gene expression changes, after two consecutive treatment periods. Through the prism
of CVD, a previous study suggested that, while the activation of immune responses may stimulate
atherosclerosis, the selective activation of immune functions may inhibit arterial inflammation [35].
Use of a low-dose polyphenol-rich aronia juice, which is achievable by food-based dietary choices, also
reflected upregulation of particular currently validated genes (IL1B and TNF), but only one enriched
Hallmark gene set. Recognizing that, in advanced atherosclerosis, a shift toward expression of CD4
+ Th2 lymphocytes over Th1 (mainly proinflammatory) happens [36], suggesting the adaptation
of the immune system to less proinflammatory, is important for the further research on the topic.
In alignment is the fact that oxLDL has both a proinflammatory and an immunostimulatory role and
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that immunization of hypercholesterolemic animals with oxLDL exerts an inhibitory action toward
atherosclerosis [37].
In addition to common proinflammatory genes, transcriptome analysis of the last treatment period
showed that OSM, RGS1, and DUSP2 were among the top DEGs following consumption of aronia
juice with a high dose of polyphenols, whereas OSM and RGS1 were also among top DEGs after
low-dose polyphenol treatment. Bioinformatic analysis revealed that both OSM and RGS1 participate in
inflammation together with TNF and IL1B. DEG lists generated after both doses of polyphenols showed
enrichment in negative regulation of cell proliferation, where OSM was a member. OSM is an IL6-type
cytokine that has both pro- and anti-inflammatory properties [38]. In diabetic mice, it was shown that
treatment with OSM alleviated cardiac ischemia/reperfusion injury through inhibition of cardiomyocyte
apoptosis and enhancement of mitochondrial biogenesis and mitochondrial function, while an adverse
outcome followed by impairment of insulin sensitivity was demonstrated in OSM receptor knockout
diabetic mice [39]. This indicates a protective role of OSM in the cardiometabolic disorders. RGS1
has a regulatory role in the migration of T and B cells and macrophages [40]. Interferon beta
treatment upregulated RGS1 gene expression, which suggests the role of RGS1 in migration of activated
immune cells to sites of inflammation, through the regulation of a cytokine–chemokine harmonization
mechanism [41]. Upregulation of RGS1 in peripheral blood T lymphocytes decreased their chemotactic
response to CXCL12 and CCL19, both implicated in atherosclerosis [40]. As many other molecular
components, which are involved in the onset and progression of CVD, RGS1 might have both beneficial
and detrimental effects which are mostly dependent on the phase of disease development [40]. Our
enrichment analysis of DEGs identified another intriguing molecular regulator, DUSP2, as a member
of the MAPK signaling pathway, following the high-dose polyphenol aronia juice consumption in the
last treatment period. DUSP2 belongs to the DUSP family of phosphatases that negatively regulate
the MAPK superfamily in mammalian cells [42]. DUSP2 transcription was induced in response to
oxidative stress and increased susceptibility to apoptosis in cell culture [43]. Its overexpression was
also demonstrated in rat cardiomyocytes during ischemia/reperfusion, while salvianolic acid A, well
known for its cardiovascular protective properties, reduced DUSP2 expression [44]. Our study failed to
provide evidence that consumption of polyphenol-rich aronia juice altered DUSP2 toward its proposed
CVD protective expression profile. Upregulation of DUSP2 in both TP3 treatments in our study is
in agreement with a comprehensive human leukocyte transcriptome analysis, in which its induction
in activated immune cells was particularly highlighted [45]. However, a recent study demonstrated
that DUSP2 negatively modulated the generation of Th17 cells in inflammation and autoimmune
response [46].
The PBMC response specific for high-dose polyphenol aronia juice intake during the last treatment
period encompassed several DEG-enriched processes related to metabolism and reactive oxygen
species: response to glucocorticoid, sequestering of triglycerides, negative regulation of lipid storage,
cellular response to oxidative stress, and regulation of reactive oxygen species metabolic process.
The latter processes shared most DEGs with the mentioned immune system-related processes, which
reflects their interdependence. Intervention studies on the PBMC transcriptome also depicted changes
in transcription of genes implicated in glucose and lipid metabolism [33,47] and release of reactive
oxygen species [48], in response to supplementation with polyphenol products. Given that we did
not detect significant changes in serum glucose and/or lipids, metabolic processes enriched in DEGs
might be associated with change(s) in some intermediate metabolic phenotype(s). Thus, TNF and
IL1B, as DEGs shared between the enriched metabolic processes, were found to affect the adipocyte
expression of fatty acid receptors [49], and changes in plasma omega-6 polyunsaturated fatty acids
and palmitic acid levels were associated with intake of the currently applied polyphenol-containing
aronia juice treatments in individuals at cardiovascular risk [50]. The accurate role of intermediate
metabolic phenotype changes in the prevention/pathogenesis of cardiometabolic diseases should be
investigated in further functional studies.
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The present research is the first to apply transcriptomics methods for identification of gene
expression changes associated with consumption of polyphenol-containing aronia juice in humans.
Due to inter-individual variability in response to polyphenol treatments [5,51], the findings should be
interpreted accordingly, as they could be relevant for the determination of specific subpopulations that
would benefit best from the use of polyphenol-containing food products, with respect to the prevention
of CVD. Although we presented longitudinal transcriptomic data and, hence, the inter-individual effects
could be reduced, our results need to be further replicated. Additionally, future intervention studies
should include CVD patients, in order to examine the possible contribution of dietary polyphenols in
the treatment of CVD.
A recent paper thoroughly reviewed the effects of foods and nutrients in different dietary scenarios
according to CVD risk outcomes, presenting the inconsistent results [52]. It points out many obstacles
toward quantification of dietary effects on CVD outcomes. Hence, our study limitations have to be
addressed. Increase in participant number is always a demand, and participant self-reporting on
treatment consumption certainly represents a study limitation. Polyphenol-rich aronia juice is a mix of
bioactive polyphenols (mostly phenolic acids and flavonoids), which limits the effect estimation of a
sole nutrient, but single-nutrient recommendation is usually less practical in both public health and
clinical practices than the food-based approach [53]. Although we cannot exclude the possibility that
intake of polyphenols originating from other foods (e.g., coffee, cocoa products, apples, olives/olive oil,
tea, and red wine) [54] could contribute to currently detected gene expression profiles, this possibility
was minimized by a study design, which included precise instructions to maintain usual habitual diet
and a follow-up on this information during the course of the study.
5. Conclusions
The present study provides details on the divergent transcriptome changes induced by prolonged
polyphenol-rich aronia juice habitual consumption in subjects at risk of CVD. Our data support the
proposed cell-specific and context-dependent effects of polyphenols. We also suggest that dietary plant
products that contain polyphenols might exert immunomodulatory effects in a complex and time-related
context of different biological pathways. Further intervention studies of prolonged consumption
of aronia products, comprising larger sample groups and adjusted doses, are needed to validate
our findings and to improve understanding of swinging proinflammatory and immune-stimulatory
properties of the discussed target genes. Functional studies are required to elucidate the exact molecular
mechanisms via which polyphenol-rich aronia products may exert cardiovascular-related effects.
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